| Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression | — | University of Texas Southwestern Medical Center | <1 mi |
| Exploring Virtual Reality Adventure Training Exergaming | N/A | The University of Texas at Arlington | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | <1 mi |
| GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | <1 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | <1 mi |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care | N/A | Elizabeth Arnold | <1 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | <1 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | <1 mi |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | <1 mi |
| To Improve Depressive Symptoms Using a Web-App | N/A | University of Texas at Austin | <1 mi |
| Confirmatory Efficacy Trial of Attention Bias Modification for Depression | Early 1 | University of Texas at Austin | <1 mi |
| Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents | N/A | University of Texas at Austin | <1 mi |
| Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression | N/A | University of Texas at Austin | <1 mi |
| SAINT in Postpartum Depression (PPD) | N/A | Magnus Medical | <1 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | <1 mi |
| Psilocybin rTMS for Treatment Resistant Depression | Phase 2 | University of Texas at Austin | <1 mi |
| Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression | Phase 4 | University of Texas at Austin | <1 mi |
| Testing FIRST in Youth Outpatient Psychotherapy | N/A | Harvard University | <1 mi |
| Clinical Trial on Agitation in Alzheimer's Dementia | Phase 2 | IGC Pharma, LLC | <1 mi |
| Cancer Pain Management Using a Web-based Intervention | N/A | University of Texas at Austin | <1 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | <1 mi |
| Parenting STAIR: Adapting a Trauma-Focused Parenting Intervention for Military-Connected Mothers and Their Children | N/A | New York University | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| Wellness App for Sleep Disturbance in Hematological Cancer Patients | N/A | The University of Texas Health Science Center at San Antonio | <1 mi |
| MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression | N/A | VA Office of Research and Development | <1 mi |
| Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) | N/A | Baylor College of Medicine | <1 mi |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| DBS for Depression | N/A | Baylor College of Medicine | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Phase 3 | Lipocine Inc. | <1 mi |
| Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Improving Adult Protective Services Client Outcomes: A Stepped-Care Social and Mental Health Engagement Program | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes | — | M.D. Anderson Cancer Center | <1 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | <1 mi |
| Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression | Phase 1 | The University of Texas Health Science Center, Houston | <1 mi |
| Transcutaneous Vagus Nerve Stimulation for Attention and Memory | N/A | Baylor College of Medicine | <1 mi |
| Improving Behavioral Health for Caregivers and Children After Pediatric Injury | N/A | Medical University of South Carolina | <1 mi |
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users | N/A | Baylor College of Medicine | <1 mi |
| Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia | N/A | GrayMatters Health Ltd. | <1 mi |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| Telehealth Behavioral Activation for Teens | N/A | Baylor College of Medicine | <1 mi |
| Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | Phase 1 | Baylor College of Medicine | <1 mi |
| Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing | N/A | Baylor College of Medicine | <1 mi |
| Deep Brain Stimulation of Treatment-Resistant Bipolar Depression | N/A | Wayne Goodman MD | <1 mi |
| Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD) | N/A | Joao L. DeQuevedo | <1 mi |
| Intracranial Investigation of Neural Circuity Underlying Human Mood | N/A | Baylor College of Medicine | <1 mi |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Phase 2 | Alto Neuroscience | <1 mi |
| Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Expansion and Evaluation of AI-generated Clinical Assessment (AI-COA®) of Depression and Anxiety Severity | N/A | Deliberate Solutions Inc. | <1 mi |
| Neonatal Neurodevelopmental Outcomes | — | Baylor College of Medicine | <1 mi |
| Physiological and Psychological Effects of Music Therapy in the Pregnant Woman and Fetus | N/A | Christina Chianis Reed | <1 mi |
| Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | <1 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| Dallas 2K: A Natural History Study of Depression | — | University of Texas Southwestern Medical Center | <1 mi |
| Accelerated rTMS for Substance Use Disorder and Depression | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services | — | Beth Israel Deaconess Medical Center | <1 mi |
| BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women | N/A | BTL Industries Ltd. | <1 mi |
| Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial) | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Combination of Novel Therapies for CKD Comorbid Depression | Phase 2 | Stony Brook University | <1 mi |
| Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression | N/A | Nader Pouratian | <1 mi |
| Recovery Through Inspiration, Support, and Empowerment | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Resilience in Adolescent Development | — | University of Texas Southwestern Medical Center | <1 mi |
| Teen Recovery Through Inspiration, Support, and Empowerment | N/A | University of Texas Southwestern Medical Center | <1 mi |
| Measurement-Based Peer Supervision App for Non-Specialist Providers | N/A | Dimagi Inc. | <1 mi |
| rTMS for Military TBI-related Depression | N/A | Henry M. Jackson Foundation for the Advancement of Military Medicine | 6 mi |
| Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma | N/A | Memorial Sloan Kettering Cancer Center | 6 mi |
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 7 mi |
| PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study | Phase 3 | Yale University | 7 mi |
| The OBSERVE Protocol | — | Yale University | 7 mi |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | Phase 2 | Seaport Therapeutics | 9 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | 13 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | 13 mi |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Phase 3 | Cybin IRL Limited | 13 mi |
| GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia | Phase 2 | Syndeio Biosciences, Inc | 13 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 18 mi |
| TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age | — | State University of New York at Buffalo | 18 mi |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Phase 3 | Xenon Pharmaceuticals Inc. | 20 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | 31 mi |